Free Trial

Mereo BioPharma Group Q4 2024 Earnings Report

Mereo BioPharma Group logo
$1.99 -0.22 (-9.95%)
As of 04/4/2025 04:00 PM Eastern

Mereo BioPharma Group EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Mereo BioPharma Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$72.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mereo BioPharma Group Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Mereo BioPharma Group Earnings Headlines

Brokers Offer Predictions for MREO FY2025 Earnings
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
What is Leerink Partnrs' Estimate for MREO Q1 Earnings?
Mereo BioPharma initiated with an Overweight at JPMorgan
See More Mereo BioPharma Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email.

About Mereo BioPharma Group

Mereo BioPharma Group (NASDAQ:MREO), a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

View Mereo BioPharma Group Profile

More Earnings Resources from MarketBeat